Breast Cancer Resistance Protein: A Potential Therapeutic Target for Cancer

Author(s): Sonali Mehendale-Munj*, Shivangi Sawant

Journal Name: Current Drug Targets

Volume 22 , Issue 4 , 2021


  Journal Home
Translate in Chinese
Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Abstract:

Breast Cancer Resistance Protein (BCRP) is an efflux transporter responsible for causing multidrug resistance (MDR). It is known to expel many potent antineoplastic drugs, owing to its efflux function. Efflux of chemotherapeutics because of BCRP develops resistance to many drugs, leading to failure in cancer treatment. BCRP plays an important role in physiology by protecting the organism from xenobiotics and other toxins. It is a half-transporter affiliated to the ATP- binding cassette (ABC) superfamily of transporters, encoded by the gene ABCG2 and functions in response to adenosine triphosphate (ATP). Regulation of BCRP expression is critically controlled at molecular levels, which help in maintaining the balance of xenobiotics and nutrients inside the body. Expression of BCRP can be found in brain, liver, lung cancers and acute myeloid leukemia (AML). Moreover, it is also expressed at high levels in stem cells and many cell lines. This frequent expression of BCRP has an impact on the treatment procedures and, if not scrutinized, may lead to the failure of many cancer therapies.

Keywords: BCRP, ABCG2, transporter, multidrug resistance, mitoxantrone-resistance protein, BCRP inhibitors.

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 22
ISSUE: 4
Year: 2021
Published on: 25 November, 2020
Page: [420 - 428]
Pages: 9
DOI: 10.2174/1389450121999201125200132
Price: $65

Article Metrics

PDF: 16